Paclitaxel nano-delivery systems: A comprehensive review

Journal of Nanomedicine and Nanotechnology

Volumn 4, Issue 2, 2013, Pages 6-

  Ma, Ping ^a   Mumper, Russell J ^a,b  

^a UNC Hamner Institute for Drug Safety Sciences   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Drug polymer conjugates; Multi drug resistance; Nanocapsules; Nanoparticles; Poly(lactic co glycolic acid); Solid lipid nanoparticles

Indexed keywords

ALBUMIN; ALCOHOL; ANG 1005; ANTINEOPLASTIC AGENT; CARBON NANOTUBE; CHITOSAN; CREMOPHOR; CYCLODEXTRIN; FATTY ACID; GELATIN; GOLD NANOPARTICLE; HYALURONIC ACID; LEP ETU; LIPOSOME; MAGNETIC NANOPARTICLE; NANOCRYSTAL; NANOGEL; NANOPARTICLE; NK 105; PACLITAXEL; PACLITAXEL POLIGLUMEX; PACLITAXEL TOCOSOL; PNU 166945; POLY (BUTYL CYANOACRYLATE); POLY (ETHYLENE GLYCOL) PHOSPHATIDYL ETHANOLAMINE; POLYASPARTIC ACID; POLYCAPROLACTONE; POLYGLACTIN; POLYGLYCEROL; POLYLACTIDE; SOLID LIPID NANOPARTICLE; TOCOSOL; UNCLASSIFIED DRUG;

BREAST CANCER; BREAST METASTASIS; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG RETENTION; GLIOMA; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; MICROEMULSION; NANO DELIVERY SYSTEM; NANOEMULSION; NANOENCAPSULATION; NEOPLASM; NEUROTOXICITY; NONHUMAN; OVARY CANCER; PATIENT ATTITUDE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; STOMACH CANCER;

EID: 84878104912     PISSN: None     EISSN: 21577439     Source Type: Journal    
DOI: 10.4172/2157-7439.1000164     Document Type: Review

References (194)

1. Jordan MA, Wilson L (2004) Microtubules as a target for anticancer drugs. Nat Rev Cancer 4: 253-265.
2. Gelderblom H, Verweij J, Nooter K, Sparreboom A (2001) Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 37: 1590-1598.
3. Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JH (1996) Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Cancer Res 56: 2112-2115.
4. Gallo JM, Li S, Guo P, Reed K, Ma J. (2003) The effect of P-glycoprotein on paclitaxel brain and brain tumor distribution in mice. Cancer Res. 63: 5114-5117.
5. Berg SL, Tolcher A, O'Shaughnessy JA, Denicoff AM, Noone M, et al. (1995) Effect of R-verapamil on the pharmacokinetics of paclitaxel in women with breast cancer. J Clin Oncol 13: 2039-2042.
6. Fracasso PM, Westervelt P, Fears CL, Rosen DM, Zuhowski EG, et al. (2000) Phase I study of paclitaxel in combination with a multidrug resistance modulator, PSC 833 (Valspodar), in refractory malignancies. J Clin Oncol 18: 1124-1134.
7. Storm G, Belliot SO, Daemen T, Lasic DD (1995) Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Advanced Drug Delivery Reviews 17: 31-48.
8. Alexis F, Pridgen EM, Langer R, Farokhzad OC (2010) Nanoparticle technologies for cancer therapy. Handb Exp Pharmacol: 55-86.
9. Wang J, Sui M, Fan W (2010) Nanoparticles for tumor targeted therapies and their pharmacokinetics. Curr Drug Metab 11: 129-141.
10. Haley B, Frenkel E (2008) Nanoparticles for drug delivery in cancer treatment. Urol Oncol 26: 57-64.
11. Suri SS, Fenniri H, Singh B. (2007) Nanotechnology-based drug delivery systems. J Occup Med Toxicol 2: 16.
12. Jain RK, Stylianopoulos T (2010) Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol 7: 653-664.
13. Jin C, Wu H, Liu J, Bai L, Guo G (2007) The effect of paclitaxel-loaded nanoparticles with radiation on hypoxic MCF-7 cells. J Clin Pharm Ther 32: 41-47.
14. Jin C, Bai L, Wu H, Liu J, Guo G, et al. (2008) Paclitaxel-loaded poly(D,Llactide-co-glycolide) nanoparticles for radiotherapy in hypoxic human tumor cells in vitro. Cancer Biol Ther 7: 911-916.
15. Danhier F, Lecouturier N, Vroman B, Jérôme C, Marchand-Brynaert J, et al. (2009) Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation. J Control Release 133: 11-17.
16. Fonseca C, Simões S, Gaspar R (2002) Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. J Control Release 83: 273-286.
17. Dong Y, Feng SS (2007) Poly(D,L-lactide-co-glycolide) (PLGA) nanoparticles prepared by high pressure homogenization for paclitaxel chemotherapy. Int J Pharm 342: 208-214.
18. Jin C, Bai L, Wu H, Song W, Guo G, et al. (2009) Cytotoxicity of paclitaxel incorporated in PLGA nanoparticles on hypoxic human tumor cells. Pharm Res 26: 1776-1784.
19. Kim BS, Kim CS, Lee KM (2008) The intracellular uptake ability of chitosancoated poly(D,L-lactideco-glycolide) nanoparticles. Arch Pharm Res 31: 1050-1054.
20. Chakravarthi SS, Robinson DH (2011) Enhanced cellular association of paclitaxel delivered in chitosan-PLGA particles. Int J Pharm 409: 111-120.
21. Bhardwaj V, Ankola D, Gupta S, Schneider M, Lehr CM, et al. (2009) PLGA nanoparticles stabilized with cationic surfactant: safety studies and application in oral delivery of paclitaxel to treat chemical-induced breast cancer in rat. Pharm Res 26: 2495-2503.
22. Mei L, Sun H, Jin X, Zhu D, Sun R, et al. (2007) Modified paclitaxel-loaded nanoparticles for inhibition of hyperplasia in a rabbit arterial balloon injury model. Pharm Res 24: 955-962.
23. Vandervoort J, Ludwig A (2002) Biocompatible stabilizers in the preparation of PLGA nanoparticles: a factorial design study. Int J Pharm 238: 77-92.
24. Mu L, Feng SS (2003) A novel controlled release formulation for the anticancer drug paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS. J Control Release 86: 33-48.
25. Feng SS, Mu L, Win KY, Huang G (2004) Nanoparticles of biodegradable polymers for clinical administration of paclitaxel. Curr Med Chem 11: 413-424.
26. Feng SS, Zeng W, Teng Lim Y, Zhao L, Yin Win K, et al. (2007) Vitamin E TPGS-emulsified poly(lactic-co-glycolic acid) nanoparticles for cardiovascular restenosis treatment. Nanomedicine (Lond) 2: 333-344.
27. Zhao L, Feng SS (2010) Enhanced oral bioavailability of paclitaxel formulated in vitamin E-TPGS emulsified nanoparticles of biodegradable polymers: in vitro and in vivo studies. J Pharm Sci 99: 3552-3560.
28. Liu Y, Pan J, Feng SS (2010) Nanoparticles of lipid monolayer shell and biodegradable polymer core for controlled release of paclitaxel: effects of surfactants on particles size, characteristics and in vitro performance. Int J Pharm 395: 243-250.
29. Feng SS, Huang G (2001) Effects of emulsifiers on the controlled release of paclitaxel (Taxol) from nanospheres of biodegradable polymers. J Control Release 71: 53-69.
30. Dong Y, Feng SS (2005) Poly(D,L-lactide-co-glycolide)/montmorillonite nanoparticles for oral delivery of anticancer drugs. Biomaterials 26: 6068-6076.
31. Sun B, Ranganathan B, Feng SS (2008) Multifunctional poly(D,L-lactideco-glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by Trastuzumab for targeted chemotherapy of breast cancer. Biomaterials 29: 475-486.
32. Wang Z, Chui WK, Ho PC (2011) Nanoparticulate delivery system targeted to tumor neovasculature for combined anticancer and antiangiogenesis therapy. Pharm Res 28: 585-596.
33. Shah N, Chaudhari K, Dantuluri P, Murthy RS, Das S (2009) Paclitaxel-loaded PLGA nanoparticles surface modified with transferrin and Pluronic® P85, an in vitro cell line and in vivo biodistribution studies on rat model. J Drug Target 17: 533-542.
34. Sahoo SK, Ma W, Labhasetwar V (2004) Efficacy of transferrin-conjugated paclitaxel-loaded nanoparticles in a murine model of prostate cancer. Int J Cancer 112: 335-340.
35. Sahoo SK, Labhasetwar V (2005) Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention. Mol Pharm 2: 373-383.
36. Dong Y, Feng SS (2004) Methoxy poly(ethylene glycol)-poly(lactide) (MPEG-PLA) nanoparticles for controlled delivery of anticancer drugs. Biomaterials 25: 2843-2849.
37. Dong Y, Feng SS (2007) In vitro and in vivo evaluation of methoxy polyethylene glycol-polylactide (MPEG-PLA) nanoparticles for small-molecule drug chemotherapy. Biomaterials 28: 4154-4160.
38. Dong Y, Feng SS (2006) Nanoparticles of poly(D,L-lactide)/methoxy poly(ethylene glycol)-poly(D,L-lactide) blends for controlled release of paclitaxel. J Biomed Mater Res A 78: 12-19.
39. Zhang Z, Feng SS (2006) In vitro investigation on poly(lactide) Tween 80 copolymer nanoparticles fabricated by dialysis method for chemotherapy. Biomacromolecules 7: 1139-1146.
40. Zhang Z, Feng SS (2006) Nanoparticles of poly(lactide)/vitamin E TPGS copolymer for cancer chemotherapy: synthesis, formulation, characterization and in vitro drug release. Biomaterials 27: 262-270.
41. Zhang Z, Feng SS (2006) Self-assembled nanoparticles of poly(lactide) --vitamin E TPGS copolymers for oral chemotherapy. Int J Pharm 324: 191-198.
42. Zhang Z, Lee SH, Gan CW, Feng SS (2008) In vitro and in vivo investigation on PLA-TPGS nanoparticles for controlled and sustained small molecule chemotherapy. Pharm Res 25: 1925-1935.
43. Zhang Z, Feng SS (2006) The drug encapsulation efficiency, in vitro drug release, cellular uptake and cytotoxicity of paclitaxel-loaded poly(lactide)-tocopheryl polyethylene glycol succinate nanoparticles. Biomaterials 27: 4025-4033.
44. Pan J, Feng SS (2008) Targeted delivery of paclitaxel using folate-decorated poly(lactide)-vitamin E TPGS nanoparticles. Biomaterials 29: 2663-2672.
45. Zhang L, Hu CH, Cheng SX, Zhuo RX (2010) Hyperbranched amphiphilic polymer with folate mediated targeting property. Colloids and Surfaces B: Biointerfaces 79: 427-433.
46. Cirstoiu-Hapca A, Buchegger F, Bossy L, Kosinski M, Gurny R, et al. (2009) Nanomedicines for active targeting: physico-chemical characterization of paclitaxel-loaded anti-HER2 immunonanoparticles and in vitro functional studies on target cells. Eur J Pharm Sci 38: 230-237.
47. Patil YB, Toti US, Khdair A, Ma L, Panyam J (2009) Single-step surface functionalization of polymeric nanoparticles for targeted drug delivery. Biomaterials 30: 859-866.
48. Jie P, Venkatraman SS, Min F, Freddy BY, Huat GL (2005) Micelle-like nanoparticles of star-branched PEO-PLA copolymers as chemotherapeutic carrier. J Control Release 110: 20-33.
49. Xiao L, Xiong X, Sun X, Zhu Y, Yang H, et al. (2011) Role of cellular uptake in the reversal of multidrug resistance by PEG-b-PLA polymeric micelles. Biomaterials 32: 5148-5157.
50. Gaucher G, Poreba M, Ravenelle F, Leroux JC (2007) Poly(N-vinylpyrrolidone)-block-poly(D,L-lactide) as polymeric emulsifier for the preparation of biodegradable nanoparticles. J Pharm Sci 96: 1763-1775.
51. Liang HF, Chen CT, Chen SC, Kulkarni AR, Chiu YL, et al. (2006) Paclitaxelloaded poly(gamma-glutamic acid)-poly(lactide) nanoparticles as a targeted drug delivery system for the treatment of liver cancer. Biomaterials 27: 2051-2059.
52. He G, Ma LL, Pan J, Venkatraman S (2007) ABA and BAB type triblock copolymers of PEG and PLA: a comparative study of drug release properties and "stealth" particle characteristics. Int J Pharm 334: 48-55.
53. Venkatraman SS, Jie P, Min F, Freddy BY, Leong-Huat G (2005) Micellelike nanoparticles of PLA-PEG-PLA triblock copolymer as chemotherapeutic carrier. Int J Pharm 298: 219-232.
54. Zhang X, Jackson JK, Burt HM (1996) Development of amphiphilic diblock copolymers as micellar carriers of Taxol. Int J Pharm 132: 195-206.
55. Ehrlich A, Booher S, Becerra Y, Borris DL, Figg WD, et al. (2004) Micellar paclitaxel improves severe psoriasis in a prospective phase II pilot study. J Am Acad Dermatol 50: 533-540.
56. Kim TY, Kim DW, Chung JY, Shin SG, Kim SC, et al. (2004) Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelleformulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res 10: 3708-3716.
57. Kim SC, Kim DW, Shim YH, Bang JS, Oh HS, et al. (2001) In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. J Control Release 72: 191-202.
58. Lim WT, Tan EH, Toh CK, Hee SW, Leong SS, et al. (2010) Phase I pharmacokinetic study of a weekly liposomal paclitaxel formulation (Genexol-PM) in patients with solid tumors. Ann Oncol 21: 382-388.
59. Lee KS, Chung HC, Im SA, Park YH, Kim CS, et al. (2008) Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res Treat 108: 241-250.
60. Saif MW, Podoltsev NA, Rubin MS, Figueroa JA, Lee MY, et al. (2010) Phase II clinical trial of paclitaxel loaded polymeric micelle in patients with advanced pancreatic cancer. Cancer Invest 28: 186-194.
61. Deshpande D, Devalapally H, Amiji MM (2008) Enhancement in anti-proliferative effects of paclitaxel in aortic smooth muscle cells upon co-administration with ceramide using biodegradable polymeric nanoparticles. Pharm Res 25: 1936-1947.
62. Van Vlerken LE, Duan Z, Seiden MV, Amiji MM (2007) Modulation of intracellular ceramide using polymeric nanoparticles to overcome multidrug resistance in cancer. Cancer Res 67: 4843-4850.
63. Devalapally H, Duan Z, Seiden MV, Amiji MM. (2007) Paclitaxel and ceramide co-administration in biodegradable polymeric nanoparticulate delivery system to overcome drug resistance in ovarian cancer. Int J Cancer 121: 1830-1838.
64. Devalapally H, Duan ZF, Seiden MV, Amiji MM. (2008) Modulation of drug resistance in ovarian adenocarcinoma by enhancing intracellular ceramide using tamoxifen-loaded biodegradable polymeric nanoparticles. Clin Cancer Res 14: 3193-3203.
65. Yadav S, van Vlerken E, Little S, Amiji MM (2009) Evaluations of combination MDR-1 gene silencing and paclitaxel administration in biodegradable polymeric nanoparticle formulations to overcome multidrug resistance in cancer cells. Cancer Chemother Pharmacol 63: 711-722.
66. Forrest M, Yáñez J, Remsberg C, Ohgami Y, Kwon G, et al. (2008) Paclitaxel prodrugs with sustained release and high solubility in poly(ethylene glycol)-b-poly (ε-caprolactone) micelle nanocarriers: pharmacokinetic disposition, tolerability, and cytotoxicity. Pharm Res 25: 194-206.
67. Xin H, Chen L, Gu J, Ren X, Wei Z, et al. (2010) Enhanced anti-glioblastoma efficacy by PTX-loaded PEGylated poly(ε -caprolactone) nanoparticles: in vitro and in vivo evaluation. Int J Pharm 402: 238-247.
68. Xin H, Jiang X, Gu J, Sha X, Chen L, et al. (2011) Angiopep-conjugated poly(ethylene glycol)-co-poly(ε-caprolactone) nanoparticles as dual-targeting drug delivery system for brain glioma. Biomaterials 32: 4293-4305.
69. Wang C, Wang Y, Wang Y, Fan M, Luo F, et al. (2011) Characterization, pharmacokinetics and disposition of novel nanoscale preparations of paclitaxel. Int J Pharm 414: 251-259.
70. Chen S, Zhang XZ, Cheng SX, Zhuo RX, Gu ZW (2008) Functionalized amphiphilic hyperbranched polymers for targeted drug delivery. Biomacromolecules 9: 2578-2585.
71. Zhang Y, Tang L, Sun L, Bao J, Song C, et al. (2010) A novel paclitaxel-loaded poly(epsilon-caprolactone)poloxamer 188 blend nanoparticle overcoming multidrug resistance for cancer treatment. Acta Biomater 6: 2045-2052.
72. Ma GL, Yang J, Zhang LH, Song CX. (2010) Effective antitumor activity of paclitaxel-loaded poly (epsilon-caprolactone)/pluronic F68 nanoparticles after intratumoral delivery into the murine breast cancer model. Anticancer Drugs 21: 261-269.
73. Zhu Z, Li Y, Li X, Li R, Jia Z, et al. (2010) Paclitaxel-loaded poly(Nvinylpyrrolidone)-b-poly(epsilon-caprolactone) nanoparticles: preparation and antitumor activity in vivo. J Control Release 142: 438-446.
74. Sheikh F, Barakat N, Kanjwal M, Aryal S, Khil M, et al. (2009) Novel selfassembled amphiphilic poly(ε-caprolactone)-grafted-poly(vinyl alcohol) nanoparticles: hydrophobic and hydrophilic drugs carrier nanoparticles. Journal of Materials Science: Materials in Medicine 20: 821-831.
75. Lee SC, Kim C, Kwon IC, Chung H, Jeong SY (2003) Polymeric micelles of poly(2-ethyl-2-oxazoline)-block-poly(ε-caprolactone) copolymer as a carrier for paclitaxel. J Control Release 89: 437-446.
76. Wang YC, Liu XQ, Sun TM, Xiong MH, Wang J (2008) Functionalized micelles from block copolymer of polyphosphoester and poly(epsilon-caprolactone) for receptor-mediated drug delivery. J Control Release 128: 32-40.
77. Sun TM, Du JZ, Yao YD, Mao CQ, Dou S, et al. (2011) Simultaneous delivery of siRNA and paclitaxel via a "two-in-one" micelleplex promotes synergistic tumor suppression. ACS Nano 5: 1483-1494.
78. Kim K, Kim JH, Park H, Kim YS, Park K, et al. (2010) Tumor-homing multifunctional nanoparticles for cancer theragnosis: simultaneous diagnosis, drug delivery, and therapeutic monitoring. J Control Release 146: 219-227.
79. Saravanakumar G, Min KH, Min DS, Kim AY, Lee CM, et al. (2009) Hydrotropic oligomer-conjugated glycol chitosan as a carrier of paclitaxel: synthesis, characterization, and in vivo biodistribution. J Control Release 140: 210-217.
80. Trickler WJ, Nagvekar AA, Dash AK (2008) A novel nanoparticle formulation for sustained paclitaxel delivery. AAPS PharmSciTech 9: 486-493.
81. Jang MK, Jeong YI, Nah JW (2010) Characterization and preparation of coreshell type nanoparticle for encapsulation of anticancer drug. Colloids Surf B Biointerfaces 81: 530-536.
82. Park JS, Han TH, Lee KY, Han SS, Hwang JJ, et al. (2006) N-acetyl histidineconjugated glycol chitosan self-assembled nanoparticles for intracytoplasmic delivery of drugs: endocytosis, exocytosis and drug release. J Control Release 115: 37-45.
83. Hu FQ, Ren GF, Yuan H, Du YZ, Zeng S (2006) Shell cross-linked stearic acid grafted chitosan oligosaccharide self-aggregated micelles for controlled release of paclitaxel. Colloids Surf B Biointerfaces 50: 97-103.
84. Paál K, Müller J, Hegedûs L (2001) High affinity binding of paclitaxel to human serum albumin. Eur J Biochem 268: 2187-2191.
85. Vogel SM, Minshall RD, Pilipovic M, Tiruppathi C, Malik AB (2001) Albumin uptake and transcytosis in endothelial cells in vivo induced by albumin-binding protein. Am J Physiol Lung Cell Mol Physiol 281: L1512-L1522.
86. Green MR, Manikhas GM, Orlov S, Afanasyev B, Makhson AM, et al. (2006) Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol 17: 1263-1268.
87. Petrelli F, Borgonovo K, Barni S (2010) Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel. Expert Opin Pharmacother 11: 1413-1432.
88. Hawkins MJ, Soon-Shiong P, Desai N (2008) Protein nanoparticles as drug carriers in clinical medicine. Adv Drug Deliv Rev 60: 876-885.
89. Kratz F (2008) Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release 132: 171-183.
90. Stinchcombe TE (2007) Nanoparticle albumin-bound paclitaxel: a novel Cremphor-EL-free formulation of paclitaxel. Nanomedicine (Lond) 2: 415-423.
91. Karmali PP, Kotamraju VR, Kastantin M, Black M, Missirlis D, et al. (2009) Targeting of albumin-embedded paclitaxel nanoparticles to tumors. Nanomedicine 5: 73-82.
92. Zhao D, Zhao X, Zu Y, Li J, Zhang Y, et al. (2010) Preparation, characterization, and in vitro targeted delivery of folate-decorated paclitaxel-loaded bovine serum albumin nanoparticles. Int J Nanomedicine 5: 669-677.
93. Gong J, Huo M, Zhou J, Zhang Y, Peng X, et al. (2009) Synthesis, characterization, drug-loading capacity and safety of novel octyl modified serum albumin micelles. Int J Pharm 376: 161-168.
94. Yadav AK, Mishra P, Agrawal GP (2008) An insight on hyaluronic acid in drug targeting and drug delivery. J Drug Target 16: 91-107.
95. Al-Ghananeem AM, Malkawi AH, Muammer YM, Balko JM, Black EP, et al. (2009) Intratumoral delivery of paclitaxel in solid tumor from biodegradable hyaluronan nanoparticle formulations. AAPS PharmSciTech 10: 410-417.
96. Saravanakumar G, Choi KY, Yoon HY, Kim K, Park JH, et al. (2010) Hydrotropic hyaluronic acid conjugates: synthesis, characterization, and implications as a carrier of paclitaxel. Int J Pharm 394: 154-161.
97. Salgueiro A, Gamisans F, Espina M, Alcober X, García ML, et al. (2002) Cyclophosphamide-loaded nanospheres: analysis of the matrix structure by thermal and spectroscopic methods. J Microencapsul 19: 305-310.
98. Huang CY, Chen CM, Lee YD (2007) Synthesis of high loading and encapsulation efficient paclitaxel-loaded poly (n-butyl cyanoacrylate) nanoparticles via miniemulsion. Int J Pharm 338: 267-275.
99. He M, Zhao Z, Yin L, Tang C, Yin C (2009) Hyaluronic acid coated poly(butyl cyanoacrylate) nanoparticles as anticancer drug carriers. Int J Pharm 373: 165-173.
100. Mitra A, Lin S (2003) Effect of surfactant on fabrication and characterization of paclitaxel-loaded polybutylcyanoacrylate nanoparticulate delivery systems. J Pharm Pharmacol 55: 895-902.
101. Kainthan RK, Muliawan EB, Hatzikiriakos SG, Brooks DE (2006) Synthesis, characterization, and viscoelastic properties of high molecular weight hyperbranched polyglycerols. Macromolecules 39: 7708-7717.
102. Mugabe C, Hadaschik BA, Kainthan RK, Brooks DE, So Al, et al. (2009) Paclitaxel incorporated in hydrophobically derivatized hyperbranched polyglycerols for intravesical bladder cancer therapy. BJU International 103: 978-986.
103. Gao Z, Lukyanov AN, Singhal A, Torchilin VP (2002) Diacyllipid-polymer micelles as nanocarriers for poorly soluble anticancer drugs. Nano Letters 2: 979-982.
104. Torchilin VP, Lukyanov AN, Gao Z, Papahadjopoulos-Sternberg B (2003) Immunomicelles: targeted pharmaceutical carriers for poorly soluble drugs. Proc Natl Acad Sci USA. 100: 6039-6044.
105. Wang J, Mongayt D, Torchilin VP (2005) Polymeric micelles for delivery of poorly soluble drugs: preparation and anticancer activity in vitro of paclitaxel incorporated into mixed micelles based on poly(ethylene glycol)-lipid conjugate and positively charged lipids. J Drug Target 13: 73-80.
106. Gao Z, Lukyanov AN, Chakilam AR, Torchilin VP (2003) PEG-PE/ phosphatidylcholine mixed immunomicelles specifically deliver encapsulated taxol to tumor cells of different origin and promote their efficient killing. J Drug Target 11: 87-92.
107. Krishnadas A, Rubinstein I, Onyüksel H (2003) Sterically stabilized phospholipid mixed micelles: in vitro evaluation as a novel carrier for waterinsoluble drugs. Pharm Res 20: 297-302.
108. Onyüksel H, Jeon E, Rubinstein I (2009) Nanomicellar paclitaxel increases cytotoxicity of multidrug resistant breast cancer cells. Cancer Lett 274: 327-330.
109. Lu Z, Yeh TK, Wang J, Chen L, Lyness G, et al. (2011) Paclitaxel gelatin nanoparticles for intravesical bladder cancer therapy. J Urol 185: 1478-1483.
110. Lu Z, Yeh TK, Tsai M, Au JL, Wientjes MG (2004) Paclitaxel-loaded gelatin nanoparticles for intravesical bladder cancer therapy. Clin Cancer Res 10: 7677-7684.
111. Yeh TK, Lu Z, Wientjes MG, Au JL (2005) Formulating paclitaxel in nanoparticles alters its disposition. Pharm Res 22: 867-874.
112. Tsai M, Lu Z, Wang J, Yeh TK, Wientjes MG, et al. (2007) Effects of carrier on disposition and antitumor activity of intraperitoneal paclitaxel. Pharm Res 24: 1691-1701.
113. Kataoka K, Kwon GS, Yokoyama M, Okano T, Sakurai Y (1993) Block copolymer micelles as vehicles for drug delivery. J Control Release 24: 119-132.
114. Hamaguchi T, Matsumura Y, Suzuki M, Shimizu K, Goda R, et al. (2005) NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel. Br J Cancer 92: 1240-1246.
115. Hamaguchi T, Kato K, Yasui H, Morizane C, Ikeda M, et al. (2007) A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation. Br J Cancer 97: 170-176.
116. Zhang JA, Anyarambhatla G, Ma L, Ugwu S, Xuan T, et al. (2005) Development and characterization of a novel Cremophor EL free liposome-based paclitaxel (LEP-ETU) formulation. Eur J Pharm Biopharm 59: 177-187.
117. Yoshizawa Y, Kono Y, Ogawara K, Kimura T, Higaki K (2011) PEG liposomalization of paclitaxel improved its in vivo disposition and anti-tumor efficacy. Int J Pharm 412: 132-141.
118. Fetterly GJ, Straubinger RM (2003) Pharmacokinetics of paclitaxel-containing liposomes in rats. AAPS PharmSci 5: E32: 90-100.
119. Bode C, Trojan L, Weiss C, Kraenzlin B, Michaelis U, et al. (2009) Paclitaxel encapsulated in cationic liposomes: a new option for neovascular targeting for the treatment of prostate cancer. Oncol Rep 22: 321-326.
120. Eichhorn ME, Ischenko I, Luedemann S, Strieth S, Papyan A, et al. (2010) Vascular targeting by EndoTAG™-1 enhances therapeutic efficacy of conventional chemotherapy in lung and pancreatic cancer. Int J Cancer 126: 1235-1245.
121. Serpe L, Catalano MG, Cavalli R, Ugazio E, Bosco O, et al. (2004) Cytotoxicity of anticancer drugs incorporated in solid lipid nanoparticles on HT-29 colorectal cancer cell line. Eur J Pharm Biopharm 58: 673-680.
122. Chen DB, Yang TZ, Lu WL, Zhang Q (2001) In vitro and in vivo study of two types of long-circulating solid lipid nanoparticles containing paclitaxel. Chem Pharm Bull (Tokyo) 49: 1444-1447.
123. Lee MK, Lim SJ, Kim CK (2007) Preparation, characterization and in vitro cytotoxicity of paclitaxel-loaded sterically stabilized solid lipid nanoparticles. Biomaterials 28: 2137-2146.
124. Li R, Eun J, Lee MK (2011) Pharmacokinetics and biodistribution of paclitaxel loaded in pegylated solid lipid nanoparticles after intravenous administration. Archives Pharm Res 34: 331-337.
125. Pandita D, Ahuja A, Lather V, Benjamin B, Dutta T, et al. (2011) Development of lipid-based nanoparticles for enhancing the oral bioavailability of paclitaxel. AAPS PharmSciTech 12: 712-722.
126. Yuan H, Miao J, Du YZ, You J, Hu FQ, et al. (2008) Cellular uptake of solid lipid nanoparticles and cytotoxicity of encapsulated paclitaxel in A549 cancer cells. Int J Pharm 348: 137-145.
127. Shenoy VS, Gude RP, Murthy RSR (2009) Paclitaxel-loaded glyceryl palmitostearate nanoparticles: in vitro release and cytotoxic activity. J Drug Target 17: 304-310.
128. Shenoy VS, Rajyaguru TH, Gude RP, Murthy RS (2009) Studies on paclitaxelloaded glyceryl monostearate nanoparticles. J Microencapsul 26: 471-478.
129. Arica-Yegin B, Benoît JP, Lamprecht A (2006) Paclitaxel-loaded lipid nanoparticles prepared by solvent injection or ultrasound emulsification. Drug Dev Ind Pharm 32: 1089-1094.
130. Koziara JM, Lockman PR, Allen DD, Mumper RJ (2004) Paclitaxel nanoparticles for the potential treatment of brain tumors. J Control Release 99: 259-269.
131. Koziara JM, Whisman TR, Tseng MT, Mumper RJ (2006) In-vivo efficacy of novel paclitaxel nanoparticles in paclitaxel-resistant human colorectal tumors. J Control Release 112: 312-319.
132. Dong X, Mattingly CA, Tseng MT, Cho S, Adams VR, et al. (2009) Development of new lipid-based paclitaxel nanoparticles using sequential simplex optimization. Eur J Pharm Biopharm 72: 9-17.
133. Dong X, Mattingly CA, Tseng MT, Cho MJ, Liu Y, et al. (2009) Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP. Cancer Res 69: 3918-3926.
134. Hureaux J, Lagarce F, Gagnadoux F, Vecellio L, Roger E, et al. (2009) Lipid nanocapsules: ready-to-use nanovectors for the aerosol delivery of paclitaxel. Eur J Pharm Biopharm 73: 239-246.
135. Lacoeuille F, Hindre F, Moal F, Roux J, Passirani C, et al. (2007) In vivo evaluation of lipid nanocapsules as a promising colloidal carrier for paclitaxel. Int J Pharm 344: 143-149.
136. Vinchon-Petit S, Jarnet D, Paillard A, Benoit JP, Garcion E, et al. (2010) In vivo evaluation of intracellular drug-nanocarriers infused into intracranial tumours by convection-enhanced delivery: distribution and radiosensitisation efficacy. J Neurooncol 97: 195-205.
137. Hureaux J, Lagarce F, Gagnadoux F, Clavreul A, Benoit JP, et al. (2009) The adaptation of lipid nanocapsule formulations for blood administration in animals. Int. J. Pharm. 379: 266-269.
138. Hureaux J, Lagarce F, Gagnadoux F, Rousselet MC, Moal V, et al. (2010) Toxicological study and efficacy of blank and paclitaxel-loaded lipid nanocapsules after i.v.administration in mice. Pharm Res 27: 421-430.
139. Roger E, Lagarce F, Garcion E, Benoit JP (2010) Reciprocal competition between lipid nanocapsules and P-gp for paclitaxel transport across Caco-2 cells. Eur J Pharm Sci 40: 422-429.
140. Roger E, Lagarce F, Benoit JP (2009) The gastrointestinal stability of lipid nanocapsules. Int J Pharm 379: 260-265.
141. Ma P, Dong X, Swadley CL, Gupte A, Leggas M, et al. (2009) Development of idarubicin and doxorubicin solid lipid nanoparticles to overcome Pgp-mediated multiple drug resistance in leukemia. J Biomed Nanotechnol 5: 151-161.
142. Wang Z, Ho PC (2010) Self-assembled core-shell vascular-targeted nanocapsules for temporal antivasculature and anticancer activities. Small 6: 2576-2583.
143. Wang Z, Ho PC (2010) A nanocapsular combinatorial sequential drug delivery system for antiangiogenesis and anticancer activities. Biomaterials 31: 7115-7123.
144. Bae KH, Lee Y, Park TG (2007) Oil-encapsulating PEO-PPO-PEO/PEG shell cross-linked nanocapsules for target-specific delivery of paclitaxel. Biomacromolecules 8: 650-656.
145. Jores K, Mehnert W, Drechsler M, Bunjes H, Johann C, et al. (2004) Investigations on the structure of solid lipid nanoparticles (SLN) and oilloaded solid lipid nanoparticles by photon correlation spectroscopy, field-flow fractionation and transmission electron microscopy. J Control Release 95: 217-227.
146. Ansell SM, Johnstone SA, Tardi PG, Lo L, Xie S, et al. (2008) Modulating the therapeutic activity of nanoparticle delivered paclitaxel by manipulating the hydrophobicity of prodrug conjugates. J Med Chem 51: 3288-3296.
147. Lundberg BB, Risovic V, Ramaswamy M, Wasan KM (2003) A lipophilic paclitaxel derivative incorporated in a lipid emulsion for parenteral administration. J Control Release 86: 93-100.
148. Perkins WR, Ahmad I, Li XG, Hirsh DJ, Masters GR, et al. (2000) Novel therapeutic nano-particles (lipocores): trapping poorly water soluble compounds. Int J Pharm 200: 27-39.
149. Stevens PJ, Sekido M, Lee RJ (2004) A folate receptor-targeted lipid nanoparticle formulation for a lipophilic paclitaxel prodrug. Pharm Res 21: 2153-2157.
150. Ma P, Benhabbour RS, Feng L, Mumper RJ (2012) 2'-Behenoyl-paclitaxel conjugate containing lipid nanoparticles for the treatment of metastatic breast cancer. Cancer Lett (In Press).
151. Bedikian AY, DeConti RC, Conry R, Agarwala S, Papadopoulos N, et al. (2011) Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanoma. Ann Oncol 22: 787-793.
152. Bradley MO, Swindell CS, Anthony FH, Witman PA, Devanesan P, et al. (2001) Tumor targeting by conjugation of DHA to paclitaxel. J Control Release 74: 233-236.
153. Bradley MO, Webb NL, Anthony FH, Devanesan P, Witman PA, et al. (2001) Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel. Clin Cancer Res 7: 3229-3238.
154. Constantinides PP, Lambert KJ, Tustian AK, Schneider B, Lalji S, et al. (2000) Formulation development and antitumor activity of a filter-sterilizable emulsion of paclitaxel. Pharm Res 17: 175-182.
155. Bulitta JB, Zhao P, Arnold RD, Kessler DR, Daifuku R, et al. (2009) Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients. Cancer Chemother Pharmacol 63: 1049-1063.
156. Kan P, Chen ZB, Lee CJ, Chu IM (1999) Development of nonionic surfactant/ phospholipid o/w emulsion as a paclitaxel delivery system. J Control Release 58: 271-278.
157. Nornoo AO, Osborne DW, Chow DS (2008) Cremophor-free intravenous microemulsions for paclitaxel: I. formulation, cytotoxicity and hemolysis. Int J Pharm 349: 108-116.
158. Nornoo AO, Chow DS (2008) Cremophor-free intravenous microemulsions for paclitaxel: II. stability, in vitro release and pharmacokinetics. Int J Pharm 349: 117-123.
159. Tiwari SB, Amiji MM (2006) Improved oral delivery of paclitaxel following administration in nanoemulsion formulations. J Nanosci Nanotechnol 6: 3215-3221.
160. Ganta S, Amiji M (2009) Coadministration of Paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. Mol Pharm 6: 928-939.
161. Khandare JJ, Jayant S, Singh A, Chandna P, Wang Y, et al. (2006) Dendrimer versus linear conjugate: influence of polymeric architecture on the delivery and anticancer effect of paclitaxel. Bioconjug Chem 17: 1464-1472.
162. Majoros IJ, Myc A, Thomas T, Mehta CB, Baker JR Jr (2006) PAMAM dendrimer-based multifunctional conjugate for cancer therapy: synthesis, characterization, and functionality. Biomacromolecules 7: 572-579.
163. Wang Y, Xin D, Liu K, Zhu M, Xiang J (2009) Heparin-paclitaxel conjugates as drug delivery system: synthesis, self-assembly property, drug release, and antitumor activity. Bioconjug Chem 20: 2214-2221.
164. Xin D, Wang Y, Xiang J (2010) The use of amino acid linkers in the conjugation of paclitaxel with hyaluronic acid as drug delivery system: synthesis, selfassembled property, drug release, and in vitro efficiency. Pharm Res 27: 380-389.
165. Wang X, Li J, Wang Y, Cho KJ, Kim G, et al. (2009) HFT-T, a targeting nanoparticle, enhances specific delivery of paclitaxel to folate receptorpositive tumors. ACS Nano 3: 3165-3174.
166. Yang D, Van S, Jiang X, Yu L (2011) Novel free paclitaxel-loaded poly(Lγ-glutamylglutamine)-paclitaxel nanoparticles. Int J Nanomedicine 6: 85-91.
167. Feng Z, Zhao G, Yu L, Gough D, Howell SB (2010) Preclinical efficacy studies of a novel nanoparticle-based formulation of paclitaxel that out-performs Abraxane. Cancer Chemother Pharmacol 65: 923-930.
168. Van S, Das SK, Wang X, Feng Z, Jin Y, et al. (2010) Synthesis, characterization, and biological evaluation of poly(L-γ -glutamyl-glutamine)-paclitaxel nanoconjugate. Int J Nanomedicine 5: 825-837.
169. Peng L, Das K, Yu L, Howell S, Gough D (2011) Coarse-grained modeling study of nonpeptide RGD ligand density and PEG molecular weight on the conformation of poly(γ-glutamyl-glutamate) paclitaxel conjugates. J Mol Model 17: 2973-87.
170. Meerum Terwogt JM, Ten Bokkel Huinink WW, Schellens JH, Schot M, Mandjes IA, et al. (2001) Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel. Anticancer Drugs 12: 315-323.
171. Galic VL, Herzog TJ, Wright JD, Lewin SN (2011) Paclitaxel poliglumex for ovarian cancer. Expert Opin Investig Drugs 20: 813-821.
172. Singer JW (2005) Paclitaxel poliglumex (XYOTAX, CT-2103): a macromolecular taxane. J Control Release 109: 120-126.
173. Gibson JD, Khanal BP, Zubarev ER (2007) Paclitaxel-functionalized gold nanoparticles. J Am Chem Soc 129: 11653-11661.
174. Oh KS, Kim RS, Lee J, Kim D, Cho SH, et al. (2008) Gold/chitosan/pluronic composite nanoparticles for drug delivery. J Appl Polym Sci 108(5):3239-3244.
175. Heo DN, Yang DH, Moon HJ, Lee JB, Bae MS, et al. (2012) Gold nanoparticles surface-functionalized with paclitaxel drug and biotin receptor as theranostic agents for cancer therapy. Biomaterials 33: 856-866.
176. Hua MY, Yang HW, Chuang CK, Tsai RY, Chen WJ, et al. (2010) Magneticnanoparticle-modified paclitaxel for targeted therapy for prostate cancer. Biomaterials 31: 7355-7363.
177. Hwu JR, Lin YS, Josephrajan T, Hsu MH, Cheng FY, et al. (2009) Targeted paclitaxel by conjugation to iron oxide and gold nanoparticles. J Am Chem Soc 131: 66-68.
178. Liu Z, Chen K, Davis C, Sherlock S, Cao Q, et al. (2008) Drug delivery with carbon nanotubes for in vivo cancer treatment. Cancer Res 68: 6652-6660.
179. Lay CL, Liu HQ, Tan HR, Liu Y (2010) Delivery of paclitaxel by physically loading onto poly(ethylene glycol) (PEG)-graft-carbon nanotubes for potent cancer therapeutics. Nanotechnology 21: 065101.
180. Sobhani Z, Dinarvand R, Atyabi F, Ghahremani M, Adeli M (2011) Increased paclitaxel cytotoxicity against cancer cell lines using a novel functionalized carbon nanotube. Int J Nanomedicine 6: 705-719.
181. Liu Y, Huang L, Liu F (2010) Paclitaxel nanocrystals for overcoming multidrug resistance in cancer. Mol Pharm 7: 863-869.
182. Liu F, Park JY, Zhang Y, Conwell C, Liu Y, et al. (2010) Targeted cancer therapy with novel high drug-loading nanocrystals. J Pharm Sci 99: 3542-3551.
183. Deng J, Huang L, Liu F (2010) Understanding the structure and stability of paclitaxel nanocrystals. Int J Pharm 390: 242-249.
184. Zhang X, Zhang X, Wu Z, Gao X, Cheng C, et al. (2011) A hydrotropic β-cyclodextrin grafted hyperbranched polyglycerol co-polymer for hydrophobic drug delivery. Acta Biomater 7: 585-592.
185. Bilensoy E, Gürkaynak O, Ertan M, Sen M, Hincal AA (2008) Development of nonsurfactant cyclodextrin nanoparticles loaded with anticancer drug paclitaxel. J Pharm Sci 97: 1519-1529.
186. Bilensoy E, Gürkaynak O, Doǧan AL, Hincal AA (2008) Safety and efficacy of amphiphilic beta-cyclodextrin nanoparticles for paclitaxel delivery. Int J Pharm 347: 163-170.
187. Memisoglu E, Bochot A, Sen M, Charon D, Duchêne D, et al. (2002) Amphiphilic beta-cyclodextrins modified on the primary face: synthesis, characterization, and evaluation of their potential as novel excipients in the preparation of nanocapsules. J Pharm Sci 91: 1214-1224.
188. Lee JY, Kim KS, Kang YM, Kim ES, Hwang SJ, et al. (2010) In vivo efficacy of paclitaxel-loaded injectable in situ-forming gel against subcutaneous tumor growth. Int J Pharm 392: 51-56.
189. Jeong B, Bae YH, Lee DS, Kim SW (1997) Biodegradable block copolymers as injectable drug-delivery systems. Nature 388: 860-862.
190. Zentner GM, Rathi R, Shih C, McRea JC, Seo MH, et al. (2001) Biodegradable block copolymers for delivery of proteins and water-insoluble drugs. J Control Release 72: 203-215.
191. Wen PY (2010) American Society of Clinical Oncology 2010: report of selected studies from the CNS tumors section. Expert Rev Anticancer Ther 10: 1367-1369.
192. Regina A, Demeule M, Che C, Lavallee I, Poirier J, et al. (2008) Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2. Br J Pharmacol 155: 185-197.
193. Mei L, Sun H, Song C (2009) Local delivery of modified paclitaxel-loaded poly(epsilon-caprolactone)/pluronic F68 nanoparticles for long-term inhibition of hyperplasia. J Pharm Sci 98: 2040-2050.
194. Kim JH, Kim YS, Kim S, Park JH, Kim K, et al. (2006) Hydrophobically modified glycol chitosan nanoparticles as carriers for paclitaxel. J Control Release 111: 228-234.